A Novel Full-Length Recombinant Human Complement Factor H (CFH; GEM103) for the Treatment of Age-Related Macular Degeneration Shows Similar In Vitro Functional Activity to Native CFH
Open Access
- 3 April 2022
- journal article
- research article
- Published by Taylor & Francis in Current Eye Research
- Vol. 47 (7) , 1087-1093
Abstract
GEM103 is a recombinantly produced full-length version of the human complement factor H (CFH) under clinical investigation for treatment of age-related macular degeneration (AMD) in individuals carrying an AMD risk-associated genetic variant of CFH. This study aimed to investigate the complement pathway-related functions of GEM103 in comparison with those of native human CFH. Key biological activities of GEM103 and human serum-derived CFH (sdCFH) were compared using four independent functional assays. Assays of C3b binding and C3 convertase decay-accelerating activity (DAA) were performed by surface plasmon resonance (SPR). Cofactor activity (CA) was measured using 8-anilinonaphthalene-1-sulfonic acid as a fluorescent probe of C3b integrity. The abilities of GEM103 and sdCFH to protect sheep erythrocytes from hemolysis by CFH-depleted normal human serum were assessed colorimetrically. In multiple SPR-based assays of C3b binding and DAA, the performance of GEM103 was consistently comparable to that of sdCFH across a range of matching concentrations. The EC50 ± SD in the fluorescence-based fluid-phase CA assay was 0.21 ± 0.06 µM for GEM103 compared to 0.20 ± 0.09 µM for sdCFH. In hemolysis assays, the EC50 value of 0.33 ± 0.16 µM for GEM103 versus 0.46 ± 0.06 µM for sdCFH were not significantly different (p = 0.81). GEM103, a recombinant CFH developed by Gemini Therapeutics, shows activity profiles comparable to sdCFH in all complement-related assays employed in this study, suggesting that GEM103 is equivalent to the native glycoprotein in terms of its in vitro functional activity. These results support further study of GEM103 as a potential therapy for AMD.Keywords
Funding Information
- Gemini Therapeutics, Inc
This publication has 33 references indexed in Scilit:
- Long-Term Effects of Vitamins C and E, β-Carotene, and Zinc on Age-related Macular DegenerationOphthalmology, 2013
- Age-related Macular Degeneration and Modification of Systemic Complement Factor H Production Through Liver TransplantationOphthalmology, 2013
- Rational Engineering of a Minimized Immune Inhibitor with Unique Triple-Targeting PropertiesThe Journal of Immunology, 2013
- Insights into the Genetic Architecture of Early Stage Age-Related Macular Degeneration: A Genome-Wide Association Study Meta-AnalysisPLOS ONE, 2013
- Complement factor H binds malondialdehyde epitopes and protects from oxidative stressNature, 2011
- Factor H and Factor H-Related Protein 1 Bind to Human Neutrophils via Complement Receptor 3, Mediate Attachment to Candida albicans , and Enhance Neutrophil Antimicrobial ActivityThe Journal of Immunology, 2009
- The disease-protective complement factor H allotypic variant Ile62 shows increased binding affinity for C3b and enhanced cofactor activityHuman Molecular Genetics, 2009
- The C-terminus of complement regulator Factor H mediates target recognition: evidence for a compact conformation of the native proteinClinical and Experimental Immunology, 2006
- Regulation of Alternative Pathway Complement Activation by Glycosaminoglycans: Specificity of the Polyanion Binding Site on Factor HBiochemical and Biophysical Research Communications, 1994
- Modulation of C3b Hemolytic Activity by a Plasma Protein Distinct from C3b InactivatorScience, 1976